North Immunology has decided its path to taking an atopic dermatitis drug into the clinic involves going public via a reverse merger.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
North Immunology has decided its path to taking an atopic dermatitis drug into the clinic involves going public via a reverse merger.